LivaNova (LIVN) fundamentals: P/E, valuation, undervalued?
LivaNova · Health Care · ref. ETF XLV · price $80.03
In short — LivaNova trades at 23.6× earnings (P/E), 17.1× forward, with a net margin of 12.8 % and revenue growth of +11 %. Read: Cheap for the growth (P/E 17 for ~288% growth (PEG 0.1)).
Is LivaNova stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$80.03+44.3% over range
Aug 28, 25low $49.57 · high $85.32Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
67% recommend buying · 6 analysts
Valuation : Cheap for the growth — P/E 17 for ~288% growth (PEG 0.1)
Valuation
23.6
P/E (price/earnings)
17.1
Forward P/E
0.08
PEG
3.3
Price/book (P/B)
$4.4B
Market cap
3.39
EPS
Profitability & growth
12.8 %
Net margin
+11 %
Revenue growth
+288 %
Earnings growth
$352M
Total debt
LivaNova income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $1.0B | $-86M | -8.4 % |
| 2023 | $1.2B | $18M | 1.5 % |
| 2024 | $1.3B | $63M | 5.0 % |
| 2025 | $1.4B | $-243M | -17.5 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is LivaNova's P/E and is the stock undervalued? What's a good P/E?
LivaNova's P/E is 23.6 (forward 17.1). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is LivaNova profitable?
LivaNova has a net margin of 12.8 % (EPS 3.39). The company is profitable.
Is LIVN stock expensive?
Our read: "Cheap for the growth" — P/E 17 for ~288% growth (PEG 0.1). Cross-check with growth and sector.
💬 A question about LivaNova? The JPI assistant answers using our backtest data.
Keep exploring LivaNova